EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tenofovir Alafenamide Versus Entecavir as Switch Therapy After Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B

Hsin-Ju Tsai, Cheng-Hao Wu, Po-Yueh Chen, Chia-Chang Chen, Ying-Cheng Lin, Shou-Wu Lee iD, Yu-Sheng Lin, Yen-Chun Peng, Teng-Yu Lee iD

Journal of Clinical Medicine · 13.08.2026 · 15 (16) · 6257

DOI: 10.3390/jcm15166257 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 13.08.2026. Verfasst von Hsin-Ju Tsai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, No. 1650, Sec. 4, Taiwan Boulevard,…. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health and Welfare, National Science and Technology Council, Taichung Veterans General Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tenofovir alafenamide (TAF) and entecavir (ETV) are recommended alternatives to tenofovir disoproxil fumarate (TDF) for patients with chronic hepatitis B (CHB) at increased risk of kidney injury. However, data from direct head-to-head comparisons of their long-term renal safety and antiviral efficacy after switching from TDF are lacking. We aimed to compare these outcomes between TAF and ETV.

Methods

This multicenter retrospective cohort study included consecutive CHB patients who switched from TDF to either TAF or ETV between January 2012 and December 2021. Inverse probability of treatment weighting using the propensity score was applied to balance the baseline characteristics. Changes in estimated glomerular filtration rate (eGFR) were assessed using a linear mixed-effects model. Renal dysfunction was defined as a decline of at least one GFR category.

Results

A total of 235 patients were included (TAF, n = 168; ETV, n = 67). After adjustment for key risk factors, the mean eGFR decline over 36 months was not significantly different between the TAF and ETV groups (−3.21 mL/min/1.73 m2 [95% CI, −4.98 to −1.44] vs. −3.49 mL/min/1.73 m2 [95% CI, −9.49 to −2.50]; p = 0.856). The 3-year cumulative incidence of renal dysfunction was also not significantly different between groups (16.6% [95% CI, 10.5–23.3] vs. 7.8% [95% CI, 2.7–16.2]; p = 0.135). Alanine aminotransferase normalization rates (83.0% vs. 78.8%; p = 0.575) and virological suppression rates (97.8% vs. 97.1%; p = 1.000) were similarly high in both groups.

Conclusions

TAF and ETV demonstrated similar long-term renal safety and antiviral efficacy, supporting both agents as reasonable switch options for CHB patients requiring TDF discontinuation because of renal safety concerns.

Schlagwörter

Stichwörter der Autor:innen

chronic hepatitis Bentecavirrenal safetytenofovir alafenamidetreatment switch

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, No. 1650, Sec. 4, Taiwan Boulevard, Taichung 407219, Taiwan.
  • Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 402202, Taiwan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi 600566, Taiwan.
  • Department of Sport, Leisure and Health Management, Tainan University of Technology, Tainan City 710302, Taiwan.
  • School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.
  • School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.

ORCID-Profile: Shou-Wu Lee, Teng-Yu Lee

Förderung

  • Ministry of Health and Welfare
  • National Science and Technology Council
  • Taichung Veterans General Hospital

Zitieren

APA

Tsai, H. J., Wu, C. H., Chen, P. Y., Chen, C. C., Lin, Y. C., Lee, S. W., Lin, Y. S., Peng, Y. C., & Lee, T. Y. (2026). Tenofovir Alafenamide Versus Entecavir as Switch Therapy After Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B. Journal of Clinical Medicine, 15(16), 6257. https://doi.org/10.3390/jcm15166257

Vancouver

Tsai HJ, Wu CH, Chen PY, Chen CC, Lin YC, Lee SW, et al. Tenofovir Alafenamide Versus Entecavir as Switch Therapy After Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B. Journal of Clinical Medicine. 2026;15(16):6257. doi:10.3390/jcm15166257

BibTeX
@article{Tsai2026,
  author = {Tsai, Hsin-Ju and Wu, Cheng-Hao and Chen, Po-Yueh and Chen, Chia-Chang and Lin, Ying-Cheng and Lee, Shou-Wu and Lin, Yu-Sheng and Peng, Yen-Chun and Lee, Teng-Yu},
  title = {Tenofovir Alafenamide Versus Entecavir as Switch Therapy After Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {16},
  pages = {6257},
  doi = {10.3390/jcm15166257}
}
Kostenlos starten →